By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Vectura Group plc 

1 Prospect West

Chippenham  Wiltshire  SN14 6FH  United Kingdom
Phone: 44-0-1249-667700 Fax: 44-0-1249-667701



Company News
Vectura (VEC.L) Release: New Findings Confirm Ultibro Breezhaler Consistently More Effective Than Seretide In Reducing COPD Flare-Ups Across Different Patient Groups 9/6/2016 10:38:58 AM
Vectura (VEC.L) Release: AirFluSal Forspiro Showed Superiority At 12 Months Over Seretide Diskus In Persistence To Treatment 8/31/2016 11:41:19 AM
Vectura (VEC.L)'s Asthma Med Flutiform Flunks Final Late-Stage Study 8/30/2016 5:52:18 AM
Lyon Manufacturing Facility Returns To Vectura (VEC.L) Upon Expiry Of Lease 7/1/2016 12:16:47 PM
Ablynx (ABLYF) To Exercise Option To License Vectura (VEC.L)’s FOX Device For Use In Its Forthcoming Phase IIb Efficacy Study Of Its Inhaled Anti-RSV Nanobody (ALX-0171) 6/28/2016 11:42:20 AM
Vectura (VEC.L) Reports Successful Completion Of VR942 Phase I Clinical Study 6/3/2016 11:00:54 AM
Vectura (VEC.L), Propeller Health Partner Up to Work on Digitally-Connected Inhalers 5/26/2016 10:35:40 AM
Ablynx (ABLYF) Reports Positive Top Line Results For Its Anti-RSV Nanobody (ALX-0171) Inhaled Using Vectura (VEC.L)’s FOX Device In A Phase I/IIa Study In Infants Hospitalized With RSV Infection 5/3/2016 9:09:07 AM
Vectura (VEC.L) Release: VR315 U.S. ANDA For Generic Advair Diskus Accepted For Filing By FDA And Milestone Payment 4/8/2016 10:43:00 AM
UK's Vectura (VEC.L) Buys Skyepharma (SKYEF) for $620 Million to Create Powerful Respiratory Company 3/16/2016 6:40:05 AM